Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Gum Tech (GUMM) -- Ignore unavailable to you. Want to Upgrade?

To: Street Walker who wrote (67)	1/28/1999 9:11:00 AM
From: OFW	Respond to of 133

PHOENIX, Jan. 28 /PRNewswire/ -- GumTech International, Inc. (Nasdaq: GUMM) announced today that it has signed a letter of intent with Gel Tech, Inc. to form a Limited Liability Corporation (LLC) to market and distribute ZICAM(TM), a new homeopathic cold remedy. Under the agreement, GumTech will own a 60% interest in the joint venture. The ZICAM(TM) product is a homeopathic nasal gel containing a patent- pending ionic emulsification formula called Zinullose(TM). Initial clinical research indicates that ZICAM(TM) significantly reduces the duration of the common cold. Researchers from Gel Tech, Inc. and Researchers with GumTech collaborated on the development of the patent over the past eighteen months. Gel Tech, Inc. is a privately held company specializing in the use of nasal gels for delivering health care products. Initial orders are currently shipping to selected retail outlets across the country. GumTech develops, manufactures, and distributes specialty chewing gum products designed to provide health benefits to consumers. The company supports its own line of branded gums and partners with major food, pharmaceutical, or marketing companies to develop and manufacture gum products under contract manufacturing agreements. GumTech operates one of the most advanced chewing gum manufacturing plants in the U.S. and is the only stainless steel gum manufacturing facility registered with the Food and Drug Administration to manufacture gum with over-the-counter drug products. GumTech is located at 246 East Watkins Street, Phoenix, Arizona 85004. (Nasdaq: GUMM) E-mail: brown@gum-tech.com GumTech Forward-Looking Statement: Certain forward-looking statements contained in this document, in particular statements concerning the efficacy of ZICAM(TM), involve a number of risks and uncertainties. Factors that could cause results to differ materially from those implied by such statements include whether ZICAM(TM) provides the benefits suggested by initial clinical research, whether ZICAM(TM) will be accepted by the market, whether ZICAM(TM) becomes subject to additional regulations, and whether ZICAM(TM) becomes subject to any litigation involving patent rights, product liabilities or consumer issues. SOURCE GumTech International, Inc. -0- 01/28/99 /CONTACT: Colleen Tiffany of The Logan Consulting Group, Inc., 716-244-7660, or logangpr@aol.com, for GumTech; or Brown Russell of GumTech International, Inc., 602-252-1617, or brown@gum-tech.com/ /Web site: gum-tech.com (GUMM)

To: Street Walker who wrote (67)	1/29/1999 2:10:00 AM
From: Bengalus	Respond to of 133

You folks are getting carried away and are going to lose money if you believe all this hype. The GunnAllen press release says, "The science behind ZICAM can be found at the ZICAM website: www.zicam.com." What do you find at this site? Not much. A central bit of text reads: "In 1995, Dr. Charles B. Hensley and Dr. R. Steven Davidson (two of Gel Tech's founders) developed the ionic free flow emulsification technology which led to their discovery of the compound, ZinulloseTM, which blocks the ability of the cold virus from binding to the ICAM-1 binding sites and from infecting the nasal cells. Subsequently, Drs. Hensley and Davidson developed ZICAMTM, a cold remedy containing ZinulloseTM designed to reduce the duration of the common cold. Subsequent double blind research demonstrated that ZICAMTM is highly effective as a treatment for the common cold, reducing the duration of the cold from 10-14 days to an average of 1.5 days (Hensley and Davidson, 1998)." The only relevant reference noted below this reads as follows: "Hensley CB and Davidson RS. Manuscript in preparation" Nothing has been demonstrated, even in the most preliminary sense, until such research is published in a peer reviewed journal. That hasn't happened. Even Quigley Corp (Nasdaq: QGLY) had two studies published in peer-reviewed journals before their Cold Eeze zinc lozenge made a splash. The enthusiastic doctor on this thread should be ashamed of himself for jumping on the bandwagon without actually noting that he has absolutely nothing to base his enthusiasm on. Cont.